Bio-Chip (BCh) technology for diagnostics of multidrug resistance (DR) of mycobacterium tuberculosis (MBT) from patients with disseminated tuberculosis (DT)

V. Zhuravlev (St.Petersburg, Russian Federation)

Source: Annual Congress 2008 - Genetics, immunology and microbiology of tuberculosis
Session: Genetics, immunology and microbiology of tuberculosis
Session type: E-Communication Session
Number: 4518
Disease area: Respiratory infections

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
V. Zhuravlev (St.Petersburg, Russian Federation). Bio-Chip (BCh) technology for diagnostics of multidrug resistance (DR) of mycobacterium tuberculosis (MBT) from patients with disseminated tuberculosis (DT). Eur Respir J 2008; 32: Suppl. 52, 4518

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

Paul Kelly - 07.10.2008 09:53
P Kelly
? how confident are you that a negative result truly predicts that drug resistance is not present.
You must Login to comment this presentation.


Related content which might interest you:
Express diagnostics of mycobacterium tuberculosis (MBT) drug resistance at disseminated tuberculosis (DT)
Source: Annual Congress 2008 - Diagnosis of tuberculosis: problems and perspectives
Year: 2008

Primary resistance (PR) of mycobacterium tuberculosis (MBT) to antimicrobial drugs (AMBD) in patients (P) with destructive pulmonary tuberculosis
Source: Eur Respir J 2004; 24: Suppl. 48, 655s
Year: 2004

Primary multidrug resistance (PMDR) of mycobacterium tuberculosis (MBT) to antimycobacterial drugs (AMBTD) in the patients with destructive TB.
Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis
Year: 2008

Recurrence after successful treatment of pulmonary tuberculosis (TB) with multidrug-resistance (MDR)
Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis
Year: 2008


Surgical treatment of destructive pulmonary tuberculosis (TB) with multi-drug resistance (MDR)
Source: Eur Respir J 2004; 24: Suppl. 48, 723s
Year: 2004

In vitro activity of triclosan ( TCN ) and thiolactomycin ( TLM ) against multi-drug-resistant ( MDR ) strains of mycobacterium tuberculosis ( M. tb )
Source: Eur Respir J 2004; 24: Suppl. 48, 722s
Year: 2004

Comparative analysis between multidrug resistant tuberculosis (MDR-TB) and extensively drug resistant tuberculosis (XDR-TB) in HIV(+) patients
Source: Annual Congress 2009 - Tuberculosis and HIV co-infection
Year: 2009


Line probe assay (LiPA) based rapid detection of multiple drug resistent (MDR) mycobacterium tuberculosis (MTB)
Source: Annual Congress 2012 - Microbiological advances in the diagnosis of tuberculosis
Year: 2012


PCR-RT for disseminated tuberculosis (DT) diagnostics
Source: Annual Congress 2008 - Diagnosis of tuberculosis: problems and perspectives
Year: 2008

Our experience in multi drug resistant tuberculosis (MDR TB) treatment
Source: Eur Respir J 2005; 26: Suppl. 49, 652s
Year: 2005

Diagnostic value of PCR-RT for the detection of DNA Mycobacterium tuberculosis complex (MBT) in blood from patient with pulmonary tuberculosis (PT)
Source: Annual Congress 2009 - Diagnostic advances in tuberculosis
Year: 2009

Laboratory system to detect multidrug-resistant (MDR) and extensively drug-resistant (XDR) mycobacterium tuberculosis strains in clinical practice
Source: Annual Congress 2008 - Epidemiological and clinical aspects of tuberculosis control
Year: 2008


Multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis: epidemiology, diagnosis and treatment
Source: Annual Congress 2008 - Infection year in review
Year: 2008


Deficient in silico selection of mycobacterium tuberculosis (MTB) epitopes in tuberculosis (TB) patients
Source: Eur Respir J 2006; 28: Suppl. 50, 801s
Year: 2006

In vitro and in vivo activity of thiourea (ISO), a mycolic acid inhibitor, against multi drug resistant (MDR) strains of Mycobacterium tuberculosis (M. tb)
Source: Eur Respir J 2005; 26: Suppl. 49, 700s
Year: 2005

Efficacy and safety of linezolid for the treatment of multidrug resistant tuberculosis (MDR-TB) and disease by non tuberculous mycobacteria (NTM)
Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions
Year: 2011

High rate of hepatitis due to treatment with pyrazinamide (PYR) and ethambutol (EMB) for latent tuberculosis infection (LTBI) in subjects exposed to MDR-TB
Source: Annual Congress 2005 - Management of tuberculosis pulmonary, extrapulmonary peculiarities
Year: 2005


Drug resistance patterns in patients with multi-drug resistant tuberculosis (MDR – TB)
Source: Annual Congress 2012 - Tuberculous and non-tuberculous mycobacterial infections: diagnostic tools
Year: 2012


The role of quantiferon tuberculosis gold test (Q) in diagnosing active tuberculosis (TB) and latent tuberculosis infection (LTI) in children
Source: Annual Congress 2008 - New tests and methods to diagnose tuberculosis infection and disease and to monitor treatment
Year: 2008


Artificial pneumothorax in the treatment of multi drug resistant tuberculosis (MDR TB)
Source: Eur Respir J 2006; 28: Suppl. 50, 586s
Year: 2006